CARGO Therapeutics | IPO Presentation Deck

Slide schematic 5/5

list 3/3 source-note 1/1 title 1/1

Components 5

bullet bullet bullet source-note headline

Tools 1

list/bullet: Positive Phase 1 results in CD19 CAR T R/R LBCL – 53% CR rate (20 of 38 patients) with ongoing durable responses in 85% of CRs (17 of 20) at median follow-up of 23 months; 120+ patients have been dosed; Init

Metrics 0

∅

No metrics

No metric insight is anchored to this slide.

Frameworks 0

∅

No frameworks

No framework match is anchored to this slide.

Find anything

The slide uses a chevron-based layout to categorize key company pillars.